Skip to main content

Selectivity Assessment of Bioanalytical Assay

Selectivity studies, also known as specificity studies, are an integral part of bioanalytical assay validation. These studies determine whether the assay can accurately measure the analyte of interest in the presence of potentially interfering substances, ensuring that the assay is specific to the analyte being measured. Here's how selectivity studies are typically performed:

Selectivity Experiment Design: The study is designed to evaluate potential interference from endogenous substances, metabolites, degradation products, or other analytes that might be present in the sample matrix. Known interfering substances, if identified, are included in the study.

Sample Preparation: A blank matrix (typically the same type of matrix as the study samples, such as plasma or urine) is prepared. The blank matrix is spiked with the analyte of interest at a low concentration (LLOQ) to mimic the lower limit of quantification.

Interfering Substances: If known interfering substances are identified, they are spiked into the blank matrix either individually or in combination with the analyte of interest. Interfering substances might include endogenous compounds, metabolites, or concomitant medications.

Analysis: The spiked samples are then analyzed using the bioanalytical assay. The goal is to determine whether the presence of interfering substances affects the accurate measurement of the analyte.

Data Analysis: The data is analyzed to determine whether the presence of interfering substances results in significant changes in the measured analyte concentration. Statistical analysis may be used to assess the impact of interference.

Acceptance Criteria: Acceptance criteria are established based on regulatory guidelines or predefined criteria. The criteria define the extent to which interference can be tolerated without compromising the accuracy of the assay.

Interpretation: If interference is observed, the laboratory must assess the potential impact on the assay's reliability. Depending on the degree of interference, corrective actions may be taken. These actions could include adjusting the assay conditions, matrix purification, or applying mathematical corrections.

Documentation: The results of the selectivity study, including any observed interferences and the laboratory's response, are thoroughly documented. This documentation serves as a record of how the assay responds to potential interferences.

Example: Selectivity Assessment for Drug Y Assay

Background:

  • Drug Y is a new investigational compound intended for treating a specific medical condition.
  • The bioanalytical assay measures the concentration of Drug Y in human plasma samples.
  • The assay must demonstrate selectivity by accurately measuring Drug Y in the presence of potentially interfering substances commonly found in plasma.

Selectivity Assessment:


Sample Preparation:

  • Prepare a set of human plasma samples as blank matrix samples (no Drug Y or interfering substances).
  • Prepare spiked samples by adding Drug Y at the lower limit of quantification (LLOQ) concentration (e.g., 5 ng/mL) to human plasma.

Interfering Substances:

  • Identify known interfering substances that could be present in plasma (e.g., endogenous compounds, metabolites, concomitant medications).

Spiking Interfering Substances:

  • Prepare spiked samples by adding the interfering substances to blank plasma samples at relevant concentrations.

Analysis:

  • Analyze the spiked samples containing Drug Y alone, spiked samples containing both Drug Y and interfering substances, and blank plasma samples using the bioanalytical assay.

Calculation of Selectivity:

  • Calculate the response (peak area or signal) of Drug Y in the presence of interfering substances and compare it to the response of Drug Y alone.

Data Interpretation:

  • If the presence of interfering substances does not significantly affect the accuracy and precision of Drug Y measurement, the assay is considered selective.
  • Calculate the percent change in response due to interference and assess whether it falls within acceptable limits (e.g., within ±20% of the response without interference).

Threshold for Selectivity:

  • Define a threshold for acceptable interference. If the response change is within this threshold, the interference is considered negligible.

Reporting:

  • Summarize the results of the selectivity assessment in the bioanalytical validation report.
  • Document the interfering substances tested, the concentrations used, and the impact on Drug Y measurement.

Conclusion:

The selectivity assessment demonstrates whether the bioanalytical assay can accurately measure Drug Y in the presence of potential interfering substances commonly found in plasma. If the assay's accuracy and precision remain within acceptable limits in the presence of these interferences, it confirms that the assay is selective for measuring Drug Y.

Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more